CSL shares plunge to 7-year low on delay in US vaccine business spinoff
Investing.com - TD Cowen raised its price target on Thermo Fisher Scientific (NYSE:TMO), a $214.7 billion market cap life sciences leader, to $654.00 from $612.00 on Thursday, while maintaining a Buy rating on the stock. According to InvestingPro data, the company maintains strong financial health with a "GOOD" overall rating.
The research firm cited Thermo Fisher’s strong third-quarter performance, which included a 5% earnings per share beat and organic growth approximately 0.5% better than expected. The company’s robust performance is reflected in its $43.2 billion trailing twelve-month revenue and consistent dividend growth of 10.3% year-over-year.
Thermo Fisher also raised its 2025 guidance, with the company maintaining its organic growth forecast. According to TD Cowen, the biopharma sector represents Thermo Fisher’s strongest market, showing mid-single-digit growth in the third quarter.
The analyst firm noted this biopharma segment is "getting stronger," specifically highlighting improvements in biotech and PPD (Thermo Fisher’s clinical research business).
TD Cowen trimmed its 2026 organic growth forecast for Thermo Fisher to 3.2%, positioning it at the low end of the company’s 3-6% range, though the firm indicated it sees "a clear upward bias" to this projection.
In other recent news, Thermo Fisher Scientific reported robust third-quarter results for 2025, surpassing analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $5.79, exceeding the forecasted $5.50. Additionally, Thermo Fisher reported revenue of $11.12 billion, which was higher than the anticipated $10.91 billion. These results reflect a positive performance and have garnered investor confidence. In related developments, Evercore ISI has raised its price target for Thermo Fisher Scientific to $610 from $590 while maintaining an Outperform rating. The research firm pointed to the company’s recent earnings report as evidence of stabilization and improvement in performance. Organic growth was slightly better than expected, driven by demand for artificial intelligence instruments in biopharma and industrial sectors. There was also a slight improvement in the analytical and diagnostic markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.